FDA Approval Rate KPI

FDA Approval Rate is a critical performance indicator that reflects the efficiency of the drug development process.

It directly influences time-to-market for new therapies, operational efficiency, and overall financial health.

A higher approval rate can lead to increased revenue potential and improved investor confidence.

Conversely, a low rate may indicate systemic issues within research and development.

Companies that excel in this metric often leverage data-driven decision-making to optimize their pipelines.

Tracking this KPI enables organizations to align their strategic goals with regulatory expectations.

How FDA Approval Rate Connects to Your Strategy

FDA Approval Rate lives inside KPI Depot's Pharmaceuticals KPI group, alongside Research & Development Expenditure, Clinical Trial Success Rate, Time to Market, Drug Pipeline Robustness, New Drug Revenue, Market Share Growth, and Operating Margin. Its priority of 3 places it just behind Research & Development Expenditure and Clinical Trial Success Rate, and ahead of the remaining five metrics in the group, so it counts among the KPI group's top three priority signals rather than a supporting one.

The KPI group assigns FDA Approval Rate to the growth perspective, the same perspective as Research & Development Expenditure and Clinical Trial Success Rate. That grouping is telling: all three track whether investment converts into a viable, expanding product line, not whether the resulting products currently sell well or run efficiently. FDA Approval Rate is the checkpoint between the two growth metrics that bracket it. Research & Development Expenditure funds the science, Clinical Trial Success Rate proves the science works in patients, and FDA Approval Rate determines whether that proof actually clears the regulator. A company can spend heavily and post strong trial results and still stall here.

The clearest tension sits with Time to Market, ranked immediately below at priority 4. Compressing Time to Market pushes teams toward earlier or thinner regulatory submissions, and the FDA can respond with a request for additional data or a rejection, which drags the approval rate down even as the speed metric improves. Drug Pipeline Robustness cuts the other way: widening the candidate pool raises the odds that some submissions target riskier, less precedented indications, which also pulls FDA Approval Rate down for reasons that have nothing to do with regulatory execution. Reading FDA Approval Rate next to either metric without knowing which one moved first is how a KPI group gets misread.

Measuring FDA Approval Rate in Practice

The formula looks simple, approvals divided by submissions, but the two counts underneath it usually live in different systems and rarely agree on what a submission is. Regulatory affairs tracks each FDA filing by application number, while R&D and clinical operations tend to think in terms of drug candidates or programs. A single candidate can generate several submissions across indications or formulations, and a single submission can pass through more than one review cycle before it closes. Before this KPI means anything, decide which unit is being counted, applications, programs, or review cycles, and hold that unit constant every time the number gets reported.

The sharpest definitional fork is what counts as an approval. KPI Depot's own definition scopes this to first review clearance, a stricter and more revealing number than a version that also credits approvals won after an initial rejection and resubmission. Blending the two hides exactly the rework and delay that leadership needs visibility into. A second fork sits in the denominator: does a withdrawn application count as a failed submission, get excluded entirely, or sit in limbo until the company refiles? Each choice changes the rate without changing anything about actual regulatory performance.

Segmentation matters more here than in most KPIs because therapeutic area and review pathway are not evenly distributed across a pipeline. A portfolio weighted toward oncology or rare disease, where expedited review pathways are common, behaves differently on this metric than one weighted toward more conventional indications, independent of how well the regulatory team is executing. Reporting one blended FDA Approval Rate across a mixed pipeline obscures which therapeutic areas or submission types are actually dragging the average down, so segment by therapeutic area and by review pathway before drawing conclusions from it.

Instrumentation pitfalls cluster around timing. The date a submission gets logged as approved needs to be the FDA's own action date, not the date the internal team learns of it or updates a tracker, or the KPI drifts away from the regulatory record. Applications still under review at the moment of reporting should stay out of both the numerator and the denominator rather than defaulting into either bucket, since counting a pending application as a failure, or dropping it silently, swings the rate depending on how heavy the pipeline happens to be that quarter.

Common Pitfalls

Many organizations overlook the importance of early-stage data quality, which can skew approval rates.

• Relying on outdated trial designs can lead to poor outcomes. This often results in wasted resources and prolonged timelines, negatively impacting overall approval rates.
• Neglecting regulatory feedback during the development process can create misalignment. Failure to incorporate insights from previous submissions can lead to repeated errors and delays.
• Inadequate patient recruitment strategies can hinder trial progress. Low enrollment rates often extend timelines and reduce the likelihood of meeting approval criteria.
• Overcomplicating clinical endpoints can confuse regulatory reviewers. Clear, concise endpoints are essential for demonstrating drug efficacy and safety.

Improvement Levers

Enhancing the FDA Approval Rate requires a focus on data integrity and strategic alignment with regulatory requirements.

• Invest in robust data management systems to ensure accurate reporting. High-quality data is crucial for meeting regulatory standards and improving approval outcomes.
• Engage with regulatory bodies early in the development process. Regular consultations can provide valuable insights and help align trial designs with expectations.
• Streamline patient recruitment efforts through targeted outreach. Utilizing digital platforms can enhance enrollment rates and ensure diverse participant representation.
• Implement rigorous training programs for clinical teams. Well-trained staff can better navigate regulatory complexities and improve submission quality.

KPI Depot is trusted by consulting, strategy, finance, and analytics teams at leading organizations worldwide, including those listed below.

FDA Approval Rate Benchmarks

We have 1 relevant benchmark in our benchmarks database.

Browse the Top Benchmarked KPIs in Pharmaceuticals

Reading the Benchmarks for FDA Approval Rate

One tracked source, ScienceDirect's synthesis of Schuhmacher et al. (2025), covers FDA Approval Rate for this page. It reports an average drawn from a population of leading research based pharmaceutical companies over the study's own observation window, which is a different animal from a single company or single drug figure: it blends companies of varying size, therapeutic focus, and regulatory experience into one result.

Before treating that result as a reference point, a customer should verify three things. First, whether the source's definition of approval means first cycle clearance only, matching KPI Depot's own definition, or whether it also folds in drugs that succeeded on a later resubmission after an initial rejection; those are two different populations even from the same pool of submissions. Second, what counts as the denominator: every submission filed, or only submissions that reached a final FDA decision inside the study window, since applications still pending at cutoff get handled differently from study to study. Third, the source does not report company size, geography, or sample size, so there is no way to tell whether the result reflects large multinationals with deep regulatory affairs teams, smaller biotechs filing their first application, or some mix of both, and that mix moves the result more than most readers expect.

OKRs That Use FDA Approval Rate

The Pharmaceuticals KPI group's OKR material uses FDA Approval Rate directly. Under the objective "Accelerate breakthrough drug development to expand our therapeutic impact," one key result reads: "Improve FDA Approval Rate from 60% to 80% for submitted drug applications." It sits beside key results for Research & Development Expenditure and Drug Pipeline Robustness, and the group's own rationale explains why: raising Clinical Trial Success Rate and FDA Approval Rate together is what actually converts R&D spending into marketable products, while a more robust drug pipeline spreads risk across more candidates so a single late-stage failure does not sink the objective.

For a customer building out this objective, that structure argues against tracking FDA Approval Rate on its own. The group's rationale treats it as a matched pair with Clinical Trial Success Rate, guarding the same outcome from two angles, so a target for one without a paired target for the other tells an incomplete story. A team can set its own goal for moving FDA Approval Rate higher over a defined period, but it only earns a place on the scorecard when it is read alongside what is happening upstream in the trials feeding it and how many viable candidates are entering the pipeline behind it.

See OKR Examples for Pharmaceuticals

Free Whitepaper

Want to achieve performance excellence in Pharmaceuticals? Download our in-depth whitepaper: Definitive Guide to Pharmaceuticals KPIs.

Download the Free Guide

KPI Categories

This KPI is associated with the following categories and industries in our KPI database: